Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00085735 · OUTCOME

Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma · Source last updated 2026-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage probability of PFS
Interval / dispersion
95% Confidence Interval
Time frame
3 years

What was measured

PFS was defined as the time interval from date of study entry to disease progression, relapse or death due to cancer or to last follow-up. Second malignancies and deaths from causes clearly not associated with tumor progression or recurrence were censored. PFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's.

Analysis population: 355 patients were classified into one of the medulloblastoma subgroups by methylation arrays and included in this analysis; 74 were Group 3 medulloblastoma, 154 were Group 4 medulloblastoma, 64 were SHH medulloblastoma, and 63 were WNT medulloblastoma patients.

Groups in this outcome

Group 3 Medulloblastoma

Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 3 medulloblastoma by methylation arrays

Group 4 Medulloblastoma

Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 4 medulloblastoma by methylation arrays

Sonic Hedgehog (SHH) Medulloblastoma

Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as SHH medulloblastoma by methylation arrays

Wingless (WNT) Medulloblastoma

Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as WNT medulloblastoma by methylation arrays

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group 3 Medulloblastoma74
Group 4 Medulloblastoma154
Sonic Hedgehog (SHH) Medulloblastoma64
Wingless (WNT) Medulloblastoma63

Reported measurements

Source class 1
Values in Percentage probability of PFS · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Group 3 Medulloblastoma70.6Not reported60.081.2Not reported
Group 4 Medulloblastoma90.6Not reported85.995.3Not reported
Sonic Hedgehog (SHH) Medulloblastoma90.4Not reported83.197.7Not reported
Wingless (WNT) Medulloblastoma98.4Not reported95.3100.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        60.0
        upper Limit
        81.2
        value
        70.6
      2. group Id
        OG001
        lower Limit
        85.9
        upper Limit
        95.3
        value
        90.6
      3. group Id
        OG002
        lower Limit
        83.1
        upper Limit
        97.7
        value
        90.4
      4. group Id
        OG003
        lower Limit
        95.3
        upper Limit
        100.0
        value
        98.4
denoms
  1. counts
    1. group Id
      OG000
      value
      74
    2. group Id
      OG001
      value
      154
    3. group Id
      OG002
      value
      64
    4. group Id
      OG003
      value
      63
    units
    Participants
description
PFS was defined as the time interval from date of study entry to disease progression, relapse or death due to cancer or to last follow-up. Second malignancies and deaths from causes clearly not associated with tumor progression or recurrence were censored. PFS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's.
dispersion Type
95% Confidence Interval
groups
  1. description
    Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 3 medulloblastoma by methylation arrays
    id
    OG000
    title
    Group 3 Medulloblastoma
  2. description
    Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as Group 4 medulloblastoma by methylation arrays
    id
    OG001
    title
    Group 4 Medulloblastoma
  3. description
    Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as SHH medulloblastoma by methylation arrays
    id
    OG002
    title
    Sonic Hedgehog (SHH) Medulloblastoma
  4. description
    Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and classified as WNT medulloblastoma by methylation arrays
    id
    OG003
    title
    Wingless (WNT) Medulloblastoma
param Type
NUMBER
population Description
355 patients were classified into one of the medulloblastoma subgroups by methylation arrays and included in this analysis; 74 were Group 3 medulloblastoma, 154 were Group 4 medulloblastoma, 64 were SHH medulloblastoma, and 63 were WNT medulloblastoma patients.
reporting Status
POSTED
time Frame
3 years
title
Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays
type
SECONDARY
unit Of Measure
Percentage probability of PFS

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice